BeiGene (BGNE) Stock Forecast & Price Target

BeiGene - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 8 Analyst Ratings

Sell
0

Hold
2

Buy
6

Consensus Price Target

$253.69
N/A

Get the Latest News and Ratings for BGNE and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for BeiGene and its competitors.

BGNE Analyst Ratings Over Time

Type	Current Forecast 1/21/24 to 1/20/25	1 Month Ago 12/22/23 to 12/21/24	3 Months Ago 10/23/23 to 10/22/24	1 Year Ago 1/21/23 to 1/21/24
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	6 Buy rating(s)	6 Buy rating(s)	5 Buy rating(s)	8 Buy rating(s)
Hold	2 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$253.69	$253.69	$246.21	$272.90
Forecasted Upside	N/A	43.73% Upside	11.60% Upside	70.80% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

BGNE Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BGNE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

BeiGene Stock vs. The Competition

Type	BeiGene	Medical Companies	S&P 500
Consensus Rating Score	2.75	2.82	2.52
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	N/A	24,741.15% Upside	12.44% Upside
News Sentiment Rating	Neutral News See Recent BGNE News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
12/3/2024	Morgan Stanley 3 of 5 stars		Reiterated Rating	Overweight	$300.00	+45.81%
11/13/2024	TD Cowen 5 of 5 stars		Boost Target	Buy ➝ Buy	$254.00 ➝ $260.00	+32.21%
10/22/2024	JPMorgan Chase & Co. 3 of 5 stars		Boost Target	Overweight ➝ Overweight	$200.00 ➝ $235.00	+7.12%
9/18/2024	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Benjamin Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Outperform	$288.00	+45.82%
8/8/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$269.00 ➝ $288.00	+57.06%
7/9/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$180.00 ➝ $152.50	+5.82%
3/27/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Market Perform ➝ Market Perform	$196.00 ➝ $161.00	+4.67%
2/27/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$350.00 ➝ $345.00	+98.62%
9/12/2023	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$259.00	+25.82%
9/11/2023	Macquarie Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$259.00	+23.78%
Get the Latest News and Ratings for BGNE and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for BeiGene and its competitors with MarketBeat's FREE daily newsletter.
8/17/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$287.00	+49.22%
6/30/2023	51job Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Downgrade
6/30/2023	22nd Century Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Downgrade
6/30/2023	3M Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Downgrade
2/28/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$213.00 ➝ $262.00	+21.28%
1/20/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$236.00 ➝ $300.00	+9.29%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 08:00 PM ET.

Should I Buy BeiGene Stock? BGNE Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, January 12, 2025. Please send any questions or comments about these BeiGene pros and cons to contact@marketbeat.com.

BeiGene
Bull Case

Here are some ways that investors could benefit from investing in BeiGene, Ltd.:

BeiGene, Ltd. reported a significant revenue increase of 28.2% year-over-year, reaching $1 billion for the latest quarter, indicating strong growth potential in the oncology market.
The company's stock is currently trading at approximately $207.23, which is near its 50-day moving average, suggesting stability in its recent performance.
With a low debt-to-equity ratio of 0.05, BeiGene, Ltd. demonstrates strong financial health and low reliance on debt, which can be attractive to risk-averse investors.
Analysts expect BeiGene, Ltd. to post a negative EPS of -5.64 for the current year, but this could indicate potential for recovery and growth in future earnings as the company continues to expand its product offerings.
The increase in short interest by 33.1% may indicate that some investors are betting against the stock, which could lead to a short squeeze if the company performs better than expected, potentially driving the stock price higher.

BeiGene
Bear Case

Investors should be bearish about investing in BeiGene, Ltd. for these reasons:

The company reported a loss of ($1.15) EPS for the latest quarter, missing the consensus estimate, which may raise concerns about its profitability and operational efficiency.
BeiGene, Ltd. has a negative net margin of 25.94%, indicating that the company is currently spending more than it earns, which could be a red flag for potential investors.
Insider selling activity has been notable, with a total of 1,136,622 shares sold in the last quarter, which may signal a lack of confidence from those closest to the company.
The stock has a P/E ratio of -21.77, reflecting that the company is not currently generating profits, which can deter investors looking for stable returns.
With a beta of 0.57, the stock is less volatile than the market, which may limit potential gains during bullish market conditions, making it less appealing for aggressive investors.

BGNE Forecast - Frequently Asked Questions

: According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for BeiGene is $253.69, with a high forecast of $345.00 and a low forecast of $152.50.
: 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BeiGene in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BGNE shares.
: According to analysts, BeiGene's stock has a predicted upside of ∞ based on their 12-month stock forecasts.
: BeiGene has been rated by research analysts at JPMorgan Chase & Co., Morgan Stanley, and TD Cowen in the past 90 days.
: Analysts like BeiGene less than other "medical" companies. The consensus rating score for BeiGene is 2.75 while the average consensus rating score for "medical" companies is 2.82. Learn more on how BGNE compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

This page (NASDAQ:BGNE) was last updated on 1/20/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BeiGene (BGNE) Stock Forecast & Price Target